Haleon Pakistan (HALEON): the Sensodyne and Panadol business spun out of GSK

KARACHI: The brands are older than the company — far older. Panadol has been Pakistan's default answer to a headache for generations, Sensodyne taught a generation of toothpaste buyers the word "sensitivity", and CaC-1000 Plus made effervescent calcium a household routine. Yet the listed company that owns these brands in Pakistan, Haleon Pakistan Limited, is one of the younger names on the Pakistan Stock Exchange: separated from GlaxoSmithKline Pakistan in 2015, listed in 2017, renamed only in January 2023. Haleon Pakistan is a case study in modern corporate surgery — a global decision, taken in London, to split consumer healthcare from prescription pharmaceuticals, executed in Karachi and Jamshoro with new letterheads but the same factory, the same brands and much the same people. This profile explains what was cut, what remained, and how a business of everyday health products actually earns its money.

Why GSK split itself in two

To understand Haleon, start with the logic of the split, because Pakistan's story is a local copy of a global one. Inside the old GSK sat two fundamentally different businesses. Prescription pharmaceuticals and vaccines are a research business: enormous spending, patent cliffs, regulator-approved prices and products chosen by doctors. Consumer healthcare is a brands business: products chosen by shoppers, growth driven by advertising, shelf presence and trust, and margins that reward marketing skill. Investors increasingly argued the two were worth more apart, where each could be judged — and managed — on its own logic.

GSK prepared the separation over years. Its consumer division was first enlarged through joint ventures: a combination with Novartis's consumer business in 2015, and then with Pfizer's consumer business in 2019, assembling a portfolio of exceptional depth. On 18 July 2022 the consumer business was demerged as Haleon plc, an independent company listed in London and New York — one of the largest listings of its kind in a decade — carrying global brands including Sensodyne, Panadol, Voltaren, Otrivin, Centrum and Advil. The name "Haleon", coined from words suggesting health and strength, was deliberately invented: a new parent for very old brands.

The Pakistan separation: 2015 to 2023

Pakistan executed its half of this story earlier than the global finale, in stages that company briefing documents lay out clearly. In 2015 the consumer healthcare business was demerged from GlaxoSmithKline Pakistan (GLAXO), forming GlaxoSmithKline Consumer Healthcare Pakistan Limited — incorporated on 31 March 2015 — alongside a separate GSK OTC (Private) Limited that held the part carved out of the GSK–Novartis joint venture. The consumer company began operating independently in 2016, with the Jamshoro manufacturing licence and marketing authorisations gathered into it, and in 2017 it was listed on the Pakistan Stock Exchange, giving the public a pure consumer-healthcare share for the first time. In January 2018 the OTC company was merged into it, leaving a single consumer entity. GLAXO continued alongside as the prescription and vaccines company — the two siblings still share ancestry, some history and a city, but no longer a balance sheet.

The final step was the name. When Haleon plc became the ultimate parent in July 2022, the Pakistani subsidiary followed: after approval by the Securities and Exchange Commission of Pakistan, GlaxoSmithKline Consumer Healthcare Pakistan Limited became Haleon Pakistan Limited on 6 January 2023. The company is a subsidiary within the Haleon group (held through Haleon Netherlands B.V., with Haleon plc as ultimate parent). Nothing about the factories, brands or products changed on that date — which is precisely the point of telling the story: a shareholder who bought "GSK Consumer" in 2017 and held it found themselves, without trading a share, an owner of "Haleon" in 2023, because the corporate family above the company had been rearranged.

Jamshoro: where Pakistan's Panadol is made

Haleon Pakistan's physical heart is its manufacturing and packaging plant at Jamshoro, in Sindh, not far from Hyderabad — the site whose licence anchored the consumer business at separation. The company's registered office sits in Karachi's Dolmen City towers in Clifton, with sales offices in Lahore, Islamabad and Multan feeding a distribution system that must reach the same pharmacies, general stores and modern trade outlets as any fast-moving consumer goods company. The Jamshoro plant does not serve Pakistan alone: company briefings describe it as supplying export markets including Vietnam and the Philippines, and in July 2025 the company announced plans to widen its export markets and expand production capacity at Jamshoro — a sign that the Pakistani plant has a role in the global group's supply network, not merely in its home market. In a country anxious about its export base, a consumer-goods factory exporting branded healthcare products to Asia is a small but telling data point.

The portfolio: everyday health, in five aisles

Haleon describes its world as "everyday health", and in Pakistan the portfolio clusters into recognisable aisles of the pharmacy. Pain relief is led by Panadol, the paracetamol brand whose name is close to generic in Pakistan, in tablet, extra-strength and children's variants. Oral health is led by Sensodyne, the sensitivity toothpaste that effectively created its category locally, alongside Parodontax, the gum-care brand the company's own reporting names with Sensodyne as its two leading oral-care franchises, and other brands from the global stable. Vitamins, minerals and supplements are led by CaC-1000 Plus, the effervescent calcium and vitamin drink-tablet long marketed for bone health. Digestive health and respiratory health round out the range with brands inherited from the old GSK consumer catalogue, among them ENO in digestive remedies. Company briefings have noted that the three leaders — Panadol, CaC-1000 Plus and Sensodyne — together account for the bulk of turnover, a concentration that is both the business's strength (three category-defining brands) and its obvious sensitivity (anything that touches those brands touches the company).

Notice what is absent: no prescription blockbusters, no vaccines, no research pipeline. Where its sibling GLAXO's value rests on a global laboratory, Haleon Pakistan's rests on brand equity accumulated over decades — the accumulated trust that makes a shopper reach for the familiar box. That asset is maintained the FMCG way: advertising, dentist and pharmacist endorsement for Sensodyne, in-store visibility, consistent quality and price points tuned to Pakistani wallets, including the small pack sizes through which much of the country's consumer market actually buys.

How consumer healthcare makes money

The revenue mechanics resemble a food or toiletries company more than a drug company. Products are manufactured at Jamshoro at scale, sold to distributors and pharmacies at trade prices, and pulled through by consumer demand the company's marketing creates. Profit is volume multiplied by the margin between shelf price and the costs of ingredients, packaging, manufacture, distribution and advertising. Three features distinguish the model within the PSX pharmaceutical sector, where Haleon is classified despite its consumer character:

• Demand is habitual, not episodic. Toothpaste is rebought monthly, pain relief kept in the drawer; revenues are steadier and less dependent on any single prescription trend than a pharma book, though they remain exposed to household budgets in inflationary years.
• Pricing sits between worlds. Some products are registered medicines subject to the Drug Regulatory Authority of Pakistan's pricing framework — paracetamol pricing decisions, for instance, directly concern Panadol — while the broader consumer range enjoys more FMCG-like flexibility, and policy moves to deregulate non-essential categories have been a recurring theme for the business.
• Inputs are global, sales are local. Active ingredients, specialised packaging and flavour and fragrance materials carry import content, so the rupee's direction matters to costs, while the Jamshoro export book provides a partial natural offset.

Everyday health as a market in its own right

Haleon's existence as a standalone sector rests on a behavioural shift its parent talks about constantly: the rise of self-care. As health systems everywhere strain, consumers treat more minor conditions themselves — reaching for a known pain reliever, a sensitivity toothpaste recommended once by a dentist, a calcium supplement a family member swears by — rather than booking a consultation for every ailment. In Pakistan that shift runs through a distinctive retail landscape: tens of thousands of independent pharmacies where the person behind the counter is often the effective adviser, general stores stocking the fastest-moving health lines, and a growing modern-trade and e-commerce fringe in the big cities. Winning in that landscape is a game of availability as much as advertising — the brand that is in stock in the small pharmacy at the moment of need takes the sale — which is why Haleon maintains regional sales offices and a distributor machine more like a consumer-goods company's than a drug maker's.

The same landscape carries the category's characteristic risks, which followers of the company will see named in its reporting: counterfeit and smuggled products that free-ride on trusted brands, price-sensitive shoppers trading down to unbranded alternatives in hard years, and the regulatory boundary between medicines, supplements and cosmetics, which determines how products may be priced and promoted. None of these is unique to Haleon, but a company whose value is concentrated in a handful of famous brands feels each of them directly. Conversely, the global group's scale brings tools a purely local rival cannot easily match — research on consumer behaviour, product formats developed for dozens of markets, and the ability to extend a Jamshoro line that proves itself in export markets. The balance between those local frictions and global resources is, in the end, the Haleon story in miniature.

Haleon in the index, and beside its sibling

Placed side by side, GLAXO and HALEON offer one of the PSX's neatest natural experiments: the same heritage, the same city, overlapping regulators — and two different economic engines, one research-and-prescription, one brand-and-shelf. Their results respond to different news, which is exactly what the global demerger was designed to reveal. Haleon's membership of the KSE-100 follows the free-float market-capitalisation process explained in how the KSE-100 is calculated and index rebalancing explained, and its classification reminds readers that exchange sector labels are conveniences: the "pharmaceuticals" basket contains both a vaccine maker and, in Haleon, a toothpaste-and-tablets consumer business.

The brands are also put to work as social instruments, in the way large consumer companies increasingly use their best-known names. Haleon Pakistan's own reporting describes a partnership with Smile Train, the international cleft charity, in which its oral-care brands were used to raise funds for children needing cleft care, and a Sensodyne campaign built around that cause won a Silver Effie award in the Positive Change – Social Good category — an advertising-industry honour, but one that shows how the company prefers to spend its marketing money: attached to the professional, expert-endorsed image on which brands like Sensodyne depend. The same reporting records a runner-up award for best corporate report in the pharmaceutical industry from the country's accountancy institutes, a small indicator that the young company has invested in the reporting habits institutional investors expect of a listed name.

Above the Pakistani company, the parent's own story has continued to simplify. Haleon plc was born with two large legacy shareholders — GSK, which had demerged it, and Pfizer, whose consumer business had been folded into the joint venture that preceded it. Both have since exited: GSK sold its remaining holding in 2024, and Pfizer disposed of its final stake in 2025, leaving Haleon a fully independent company with no former parent on its register. For the Karachi-listed subsidiary nothing structural changed — its brands, plant and reporting line run as before — but the group's strategy is now set by a board answerable to no pharmaceutical parent, which is the end-state the 2022 demerger always implied. Management briefings in Pakistan have meanwhile described the next physical chapter: a major expansion of the Jamshoro plant centred on Panadol capacity, intended to support wider exports into Southeast Asia and Africa, markets where export certification alone can take two to four years to secure. The direction of travel is consistent — a consumer plant in Sindh being groomed as a supply source for the region, not only for its home shelves.

What followers of Haleon Pakistan typically watch

Observers tend to watch the health of the three leading brands and any category data on oral care, pain relief and supplements; DRAP pricing developments affecting registered products; the Jamshoro capacity expansion and export progress; advertising intensity relative to FMCG competitors; and input-cost and currency movements through the margin. Announcements from the London parent about the global portfolio occasionally reshape local expectations, since brand ownership and strategy sit at group level. This profile is educational content, not financial advice: those are lenses for reading the business, not a recommendation to buy or sell HALEON shares. Aktzien, the investing app being built for Pakistan, plans to present demergers and spin-offs in exactly this narrative form, and its learning library covers the underlying ideas — what a demerger is, how brands create value, and how to read a consumer company's accounts.

Key takeaway: Haleon Pakistan is the consumer-healthcare half of the old GSK in Pakistan — demerged in 2015, listed in 2017, renamed for its new global parent in 2023 — earning its living from trusted everyday brands such as Panadol, Sensodyne and CaC-1000 Plus, made at Jamshoro and sold like consumer goods, not prescription drugs.